Company news

Prothena Corporation plc news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Prothena Announces Appointment of Billy Dunn, M.D., to its Board of Directors

May 15, 2023

Prothena Reports First Quarter 2023 Financial Results and Business Highlights

May 3, 2023

Prothena to Report First Quarter 2023 Financial Results on May 4

April 26, 2023

Prothena Presents New Preclinical Data Supporting Best-in-Class Profile of PRX012, a Next-Generation Anti-Amyloid Beta Antibody, at AD/PD 2023

March 30, 2023

Prothena Reports Fourth Quarter and Full Year 2022 Financial Results, and Provides Financial Guidance and Business Highlights

February 22, 2023

Prothena to Report Fourth Quarter and Full Year 2022 Financial Results on February 23, 2023

February 15, 2023

Prothena Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

February 2, 2023

Prothena Reports Topline Phase 1 Single Ascending Dose Study Results of PRX005, a Novel Anti-MTBR-Tau Antibody for the Potential Treatment of Alzheimer’s Disease

January 30, 2023

Prothena Announces Pricing of Public Offering of 3,250,000 Ordinary Shares

December 13, 2022

Prothena Announces Proposed Public Offering of Ordinary Shares

December 12, 2022

Prothena Announces Achievement of $40 Million Clinical Milestone Payment from Novo Nordisk for PRX004/NNC6019 Under Investigation for the Treatment of ATTR Cardiomyopathy

November 20, 2022

Prothena Reports Third Quarter 2022 Financial Results and Business Highlights

November 2, 2022

Prothena to Report Third Quarter 2022 Financial Results on November 3rd

October 26, 2022

Prothena Announces Appointment of Biotechnology Industry Leader Helen S. Kim to its Board of Directors

August 31, 2022

Prothena Reports Second Quarter 2022 Financial Results and Business Highlights

August 7, 2022

Prothena to Report Second Quarter 2022 Financial Results on August 8th

July 31, 2022

Prothena Reports First Quarter 2022 Financial Results and Business Highlights

May 4, 2022

Prothena to Report First Quarter 2022 Financial Results on May 5th

April 27, 2022

Prothena Receives FDA Fast Track Designation for PRX012, a Next-Generation Anti-Amyloid Beta Antibody Under Investigation for the Treatment of Alzheimer’s Disease

April 25, 2022

Prothena Announces FDA Clearance of IND for PRX012, a Subcutaneous Anti-Amyloid Beta Antibody Under Investigation for the Treatment of Alzheimer’s Disease

March 27, 2022

Prothena Presents New Data for Alzheimer’s and Parkinson’s Disease Programs at AD/PD 2022

March 15, 2022

Prothena Reports Fourth Quarter and Full Year 2021 Financial Results, and Provides Financial Guidance and Business Highlights

February 16, 2022

Prothena to Report Fourth Quarter and Full Year 2021 Financial Results and Host Webcast Conference Call on February 17, 2022

February 9, 2022

Prothena Reports Third Quarter 2021 Financial Results and Business Highlights

November 3, 2021

Prothena to Report Third Quarter 2021 Financial Results on November 4th

October 27, 2021

Prothena Announces Executive Appointments

September 30, 2021

Prothena Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

September 2, 2021

Prothena Reports Second Quarter 2021 Financial Results and Business Highlights

August 4, 2021

Prothena to Report Second Quarter 2021 Financial Results on August 5th

July 28, 2021

Prothena Presents New Data from Robust Alzheimer’s Portfolio at the Alzheimer’s Association International Conference 2021

July 25, 2021

Prothena and Novo Nordisk Announce Acquisition Agreement for Prothena’s ATTR Amyloidosis Programme

July 11, 2021

Prothena Announces Bristol Myers Squibb Opt-in of Anti-Tau PRX005 as the First Program from Global Neuroscience Research and Development Collaboration

June 23, 2021

Prothena Announces Appointment of Sanjiv Patel, MBBS, to its Board of Directors

May 19, 2021

Prothena Reports First Quarter 2021 Financial Results and Provides Updated Financial Guidance and R&D Update

May 10, 2021

Prothena Announces Achievement of $60 Million Milestone From Roche for First Patient Dosed in Phase 2b Study of Prasinezumab in Early Parkinson’s Disease

May 9, 2021

Prothena to Report First Quarter 2021 Financial Results on May 11th

May 3, 2021

Prothena Presents Phase 1 Study Results of PRX004 in Oral Presentation at AAN 2021

April 17, 2021

Prothena Announces PRX004 Phase 1 Study Results Selected for Emerging Science Oral Presentation at AAN 2021

April 14, 2021

Prothena Announces Appointment of Hideki Garren, MD, PhD, as Chief Medical Officer

April 4, 2021

Prothena Announces Pricing of Public Offering of 3,500,000 Ordinary Shares

March 23, 2021

Prothena Announces Proposed Offering of Ordinary Shares

March 22, 2021

Prothena Announces Promising New Preclinical and Clinical Data from its Neurodegenerative Programs Selected for Oral Presentations at AD/PD 2021

February 23, 2021

Prothena Reports Fourth Quarter and Full Year 2020 Financial Results, and Provides Financial Guidance and R&D Update

February 10, 2021

Prothena to Report Fourth Quarter and Full Year 2020 Financial Results and Host Webcast Conference Call on February 11th

February 3, 2021

Prothena Announces Confirmatory Phase 3 AFFIRM-AL Study of Birtamimab in Mayo Stage IV Patients with AL Amyloidosis under SPA Agreement with FDA

January 31, 2021

Prothena Reports Positive 9 Month Results from Phase 1 Long-term Extension Study of PRX004, the First Investigational Anti-Amyloid Immunotherapy for the Treatment of ATTR Amyloidosis

December 8, 2020

Prothena Reports Third Quarter 2020 Financial Results and Provides R&D Update

November 3, 2020

Prothena Announces Presentations on Two Programs from its Alzheimer’s Disease Portfolio at CTAD 2020

November 3, 2020

Prothena to Report Third Quarter 2020 Financial Results on November 4

October 27, 2020

Prothena Announces Updated Timing of Presentation for Phase 2 PASADENA Study Results at International Congress of Parkinson’s Disease and Movement Disorders

September 2, 2020

← Newer news releases · Older news releases →

Calls

The 5 newest of 6 calls. Every call is listed under its year.

Decks

The 5 newest of 10 decks. Every deck is listed under its year.